Company / PP&E (Net)
Biogen PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.1B
FY2025
5-year range
$3.1B / $3.4B
FY2021-FY2025
Trend
-4.0%
vs FY2024
Sector context
#11 of 195
Health Care
What the data says
Among 195 Health Care companies, Biogen is in the top 6% for pp&e (net). PP&E (Net) has fluctuated over the past 10 years, ranging from $2.5B in FY2016 to $3.6B in FY2018.
Based on SEC 10-K filings.
$3.1B in FY2025 with a 5-year CAGR of -2.2%. Top quartile in the Health Care sector.
Declined from $3.3B to $3.1B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -2.5%
- 5-Year CAGR
- -2.2%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 195This company $3.1B Sector average $770.1M
▼
+296.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.2%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 4.0% year-over-year.
- Ranks #11 out of 195 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.1B | -4.0% |
| FY2024 | $3.2B | -3.9% |
| FY2023 | $3.3B | +0.3% |
| FY2022 | $3.3B | -3.4% |
| FY2021 | $3.4B | +0.1% |
| FY2020 | $3.4B | +5.1% |
| FY2019 | $3.2B | -9.8% |
| FY2018 | $3.6B | +13.2% |
| FY2017 | $3.2B | +27.2% |
| FY2016 | $2.5B | +14.4% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026